Myeloperoxidase is Associated with Insulin Resistance and Inflammation in Overweight Subjects with First-degree Relatives with Type 2 Diabetes Mellitus
Overview
Authors
Affiliations
Background: Family history of type 2 diabetes mellitus (T2DM) is one of risk factors for that in future a subject can develop diabetes. Insulin resistance (IR) is important in the pathogenesis of T2DM. There is evidence that oxidative stress plays an important role in the etiology and/or progression of diabetes. Myeloperoxidase (MPO) participates in developing of inflammation. The objective was to investigate if MPO is associated with IR and inflammation in individuals with first-degree relatives of T2DM.
Methods: Cross-sectional study in 84 overweight individuals with family history of T2DM divided in two groups according to IR, group with IR (homeostasis model assessment [HOMA] ≥2.5; n=43) and control group (CG; HOMA <2.5; n=41). Complete clinical history and a venous blood sample were collected for measuring glucose and lipids profile, insulin, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), MPO, glutathione reductase (GRd), glutathione peroxidase, and superoxide dismutase.
Results: MPO, TNF-α, and IL-6 were higher in patients with IR than in CG (MPO: 308.35 [190.85 to 445.42] vs. 177.35 [104.50 to 279.85], P=0.0001; TNF-α: 13.46 [10.58 to 18.88] vs. 9.39 [7.53 to 11.25], P=0.0001; IL-6: 32.93 [24.93 to 38.27] vs. 15.60 [12.93 to 26.27]; P=0.0001, respectively). MPO was associated with IR (rho de Spearman=0.362, P=0.001). In the analysis of lineal regression, MPO predicts IR (β, 0.263; t, 2.520; P=0.014). In the univariate analysis, MPO had an odds ratio of 9.880 for risk of IR (95% confidence interval, 2.647 to 36.879).
Conclusion: MPO had relation with IR and inflammation parameters in overweight subjects with first-degree relatives of T2DM. We need studies on a casual relationship and molecular mechanisms among the increased serum MPO levels, inflammation markers, and IR.
Effect of Diet on HDL in Obesity.
Bacchetti T, Morresi C, Simonetti O, Ferretti G Molecules. 2025; 29(24.
PMID: 39770044 PMC: 11677490. DOI: 10.3390/molecules29245955.
Mastrototaro L, Apostolopoulou M, Hartwig S, Strassburger K, Lipaeva P, Trinks N EBioMedicine. 2024; 110:105471.
PMID: 39626509 PMC: 11652844. DOI: 10.1016/j.ebiom.2024.105471.
Neutrophils as indicators of obesity-associated inflammation: A systematic review and meta-analysis.
Gomez-Casado G, Jimenez-Gonzalez A, Rodriguez-Munoz A, Tinahones F, Gonzalez-Mesa E, Murri M Obes Rev. 2024; 26(3):e13868.
PMID: 39610288 PMC: 11791391. DOI: 10.1111/obr.13868.
Marchan-Figueroa Y, Tepec-Casarrubias B, De la Cruz-Mosso U, Astudillo-Lopez C, Matia-Garcia I, Salgado-Goytia L Nutrients. 2024; 16(22).
PMID: 39599716 PMC: 11597308. DOI: 10.3390/nu16223930.
Claveles Casas F, Barrera F, Lopez C, Chacon I Del V, Di Sciullo M, Ramirez D Open J Pharm Sci Res. 2024; 1(1):123-133.
PMID: 39450269 PMC: 11500055. DOI: 10.36811/ojpsr.2019.110006.